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Abstract 
On March 29, 2017, a European Summit on the Prevention and Self-Management of Chronic Respiratory Diseases 
(CRD) was organized by the European Forum for Research and Education in Allergy and Airway Diseases. The event 
took place in the European Parliament of Brussels and was hosted by MEP David Borrelli and MEP Sirpa Pietikainen. 
The aim of the Summit was to correspond to the needs of the European Commission and of patients suffering from 
CRD to join forces in Europe for the prevention and self-management. Delegates of the European Rhinologic Society, 
European Respiratory Society, European Academy of Allergy and Clinical Immunology, European Academy of Paedi-
atrics, and European Patients Organization EFA all lectured on their vision and action plan to join forces in achieving 
adequate prevention and self-management of CRD in the context of Precision Medicine. Recent data highlight the 
preventive capacity of education on optimal care pathways for CRD. Self-management and patient empowerment 
can be achieved by novel educational on-line materials and by novel mobile health tools enabling patients and doc-
tors to monitor and optimally treat CRDs based on the level of control. This report summarizes the contributions of 
the representatives of different European academic stakeholders in the field of CRD.
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Background
The World Health Organization (WHO) rates Chronic 
Respiratory Diseases (CRD) as one of the 4 major chronic 
diseases of mankind (Fig. 1) [1]. CRD often start in early 
childhood and persist throughout the life cycle. They are 
a major cause of economic burden and largely impact on 
the general society. CRD represent a major global health 
problem leading to gender and social inequalities within 
and between countries [2]. CRD including allergies 
and chronic rhinosinusitis (CRS) are complex diseases 
intertwined with ageing. Asthma, CRS and allergic rhi-
nitis (AR) are the most common non-communicable 
diseases in children and adults, and their prevalence and 
burden have increased in recent decades, reaching epi-
demic proportions [3–5]. The Polish Presidency of the 
Council of the European Union (EU) has therefore made 
prevention, early diagnosis and treatment of CRD a pri-
ority for the EU’s public health policy [6] to prepare the 
Conclusions of the Council, December 2, 2011 [7]. This 
was reinforced by the Cyprus Presidency of the EU Coun-
cil [8]. In October 2015, a symposium on Precision Medi-
cine in Allergy and Airway diseases was organized in the 
EU parliament with active participation of the Commis-
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integrated health system, built around systems and Preci-
sion Medicine and strategic partnerships, was proposed 
to combat CRD [10–13]:
  • To better understand genetic determinants, environ-
mental factors, molecular and cellular mechanisms 
underlying CRDs.
  • To investigate social and economic factors leading to 
the onset, persistence and severity of CRDs.
  • To phenotype and endotype patients, allowing imple-
mentation of the key pillars of Precision Medicine, 
i.e. personalized care, participation of the patient, 
prediction of success of treatment and prevention of 
disease.
  • To develop unbiased and accurate biomarkers for 
multimorbidities, severity and follow-up of patients.
  • To propose novel care pathways including multimor-
bidity and self-management strategies.
  • To implement the principles of Precision Medicine 
into daily practice, in particular in primary care.
  • To coach self-empowered patients through novel 
mobile health tools.
  • To implement integrated care pathways with uniform 
information and treatment strategies provided by dif-
ferent care providers seen by patients.
A multidisciplinary practical platform with all stake-
holders involved in CRD is currently missing. A sympo-
sium at the EU Parliament in October 2015 [9] proposed 
that the implementation of Precision Medicine into 
clinical practice may help to achieve the arrest of the epi-
demic of allergies and CRD. Participants underscored the 
need for optimal patient care in Europe, supporting joint 
action plans for disease prevention, patient empower-
ment, and cost-effective treatment strategies [9]. In the 
meantime, EUFOREA elaborated a European consensus 
report on the guidance of clinicians into the implementa-
tion of the principles of PM in daily practise [13].
The European Union Parliament Summit on March 
29, 2017 aimed at providing practical approaches on the 
prevention and self-management of CRD, proposing care 
pathways implementing emerging technologies for pre-
dictive medicine centred around the patient (Figs. 2, 3). 
The Summit involved the active contribution of the sci-
entific societies and patients’ organisations, allowing a 
discussion on the innovative EUFOREA approaches to 
move forward on the prevention and self-management of 
CRD.
The vision, mission and objectives of EUFOREA
EUFOREA is an international non-profit organisation 
forming an alliance of all stakeholders from national and 
international organizations, institutions, and agencies 
Fig. 1 Chronic airway disease
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Fig. 2 Programme announcement of EU Summit
Fig. 3 Faculty portrait
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working towards the common vision of preventing and 
improving the burden of asthma, allergic airway diseases 
and CRS. EUFOREA proposes to reduce the preventable 
and avoidable burden of morbidity and disability due to 
CRD by means of a multidisciplinary practical approach 
with all stakeholders at national, regional and global lev-
els. Its aim is for populations to reach the highest attain-
able standards of health and productivity at every age and 
for CRD to no longer present as a barrier to well-being or 
socio-economic development. Given the novel scientific 
data on the prediction and prevention of allergic and airway 
diseases, the cost of inaction is unacceptable and there is 
an urgent need to undertake integrated actions in Europe, 
joining forces in a multi-specialty way with all stakeholders.
The main objective of EUFOREA is to initiate a com-
prehensive approach to prevent and fight CRD in upper 
and lower airways via the following strategies:
  • To better educate the patients, the (para)medical 
community and the public
  • To develop innovative care pathways including the 
key principles of Precision Medicine, i.e. prevention, 
personalized care, prediction and participation
  • To empower the patients at the centre of the strategy, 
and to promote self-management and primary care
  • To educate patients and health care providers on the 
optimal care pathways for CRD, taking into account 4 
approaches: prevention, prediction, participation and 
personalized care
  • To make recommendations of simple strategies for 
chronic airway disease management using emerging 
technologies for predictive medicine
  • To promote active and healthy ageing
  • To improve the work productivity of chronic airway 
disease sufferers
  • To improve the well-being of chronic airway disease 
sufferers
  • To reduce health and social inequities
  • To support academic research in Europe in the field 
of CRD through a unique research support platform.
The added value of EUFOREA is to develop a unique 
strategic partnership for the prevention and control of 
CRD in order to tackle all components of prevention and 
to combat CRD from basic science to policies. EUFOREA 
provides a network through which collaborating parties 
can combine their strengths, thereby achieving major 
results that no one single partner could obtain alone. 
EUFOREA is meeting the need for a pan-European multi-
stakeholder platform for the development of optimal and 
integrated care pathways for CRD, through a coordinated 
research and education activity portfolio. The EUFOREA 
platform unites educational and research initiatives of 
all relevant stakeholders dealing with CRD through rep-
resentatives of their official organizations: Primary Care 
physicians, Paediatricians and Allergologists via EAACI 
(European Academy of Allergy and Clinical Immunol-
ogy), Respiratory physicians via ERS (European Respira-
tory Society), ENT doctors via ERS (European Rhinology 
Society), Allergy specialists of the ARIA (Allergic Rhini-
tis and its Impact on Asthma) expert group, Rhinologists 
of the EPOS expert committee, Patient organizations via 
EFA (European Federation of Allergy and Asthma Patient 
Organization), and Pharmacists via PGEU (Pharmaceuti-
cal Group at the European Parliament). The EUFOREA 
platform is unique given the multi-specialty nature and 
high academic profile of the multi-specialty advisory 
board taking part in the educational and clinical research 
activities of EUFOREA.
EUFOREA attempts to improve coordination between 
existing EU, governmental and non-governmental pro-
grammes to avoid duplication of efforts and wasting of 
resources.
Action plan of EUFOREA
1. ARIA Care pathways implementing emerging tech-
nologies for predictive medicine in rhinitis and 
asthma across the life cycle
The Allergic Rhinitis and its Impact on Asthma (ARIA) 
initiative commenced during a WHO workshop in 1999 
and was developed and implemented by the WHO Col-
laborating Centre on Asthma and Rhinitis [14, 15]. The 
initial goals were:
  • To propose a new AR classification,
  • To promote the concept of multi-morbidity in 
asthma and rhinitis, and
  • To develop guidelines with all stakeholders that could 
be used globally for all countries and populations, in 
particular developing countries.
ARIA—disseminated and implemented in over 70 
countries globally [16]—is now focusing on the imple-
mentation of emerging technologies for individualized 
and predictive medicine. MASK (MACVIA (Contre les 
MAladies Chroniques pour un VIeillissement Actif) [17]—
ARIA Sentinel NetworK) [18] uses mobile technology to 
develop care pathways for the management of rhinitis 
and asthma by a multi-disciplinary group and by patients 
themselves. An App (Android and iOS) is available in 21 
countries and 16 languages. It uses a visual analogue scale 
to assess symptom control and work productivity as well 
as a clinical decision support system. It is associated with 
an inter-operable tablet for physicians and other health 
care professionals. The scaling up strategy uses the rec-
ommendations of the European Innovation Partnership 
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on Active and Healthy Ageing. The aim of the novel 
ARIA approach is to provide well-being and an active 
and healthy life to rhinitis sufferers, whatever their age, 
sex or socio-economic status, in order to reduce health 
and social inequalities incurred by the disease [19].
2. EUFOREA mobile application ‘mySinusitisCoach’ 
CRS as a model for optimal patient coaching and 
empowerment
CRS is a common disease but a stratification strategy is 
needed to provide a satisfactory management and to avoid 
unnecessary surgical interventions. MySinusitisCoach is 
being developed by EUFOREA, following a unique strat-
egy with the following phases of development:
1. European CRS patient days to explore the needs and 
obstacles in current CRS care, including feedback on 
the mySinusitisCoach prototype using emerging tech-
nologies and the proposal of CRS interactive educa-
tional materials.
2. European meeting to align the patients’ needs and 
KOL vision on the mySinusitisCoach prototype 
(Fig. 4), with feedback on the unique educational and 
coaching strategy of the CRS patients by mySinusitis-
Coach.
3. Preparation of the implementation of mySinusitis-
Coach in several regions in Europe with the support 
of local governmental authorities.
4. Analyses of the data generated by mySinusitisCoach, 
showing socio-economic value, secondary and ter-
tiary prevention of CRD
5. Deployment of mySinusitisCoach in Europe, with 
data on real-life burden and cost of disease, (in)effec-
tive current treatment strategies, and demonstration 
of the major benefit of the instalment of mySinusitis-
Coach for the patient and the society.
3. EUFOREA Educational Platform: a practical approach
Patient education is the process by which health pro-
fessionals and others impart information to patients and 
their caregivers that will alter their health behaviour or 
Fig. 4 EUFOREA ‘mySinusitisCoach’
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improve their health status. Patient education for patients 
with chronic upper airway disease is one of the main-
stays of EUFOREA (Fig. 5). European experts made a list 
of questions asked in their daily practice. Subsequently, 
interviews with small group of patients, individually and 
in groups, about their information needs were organized 
for understanding the patients’ needs. A large web-based 
interview about information needs was then elaborated. 
Patients indicated that they needed more information at 
all stages of their disease and that they were not satisfied 
with the information available on the internet or from 
other sources. Patients were mostly interested to receive 
their information by means of a website or an App. Fur-
thermore, they were very enthusiastic about the possi-
bility of consulting a sinusitis coach (trained healthcare 
professional) by mail, chat or telephone. The EUFOREA 
website already contains the first series of patient 
information.
4. EUFOREA Respiratory Research Platform for defining 
the RESEARCH NEEDS AND PRIORITIES in Europe
In November 2016, brainstorming sessions were held 
during the European Rhinology Research Forum (ERRF) 
on the research needs and priorities in the field of CRD 
with active participants from all over Europe. The major 
unmet needs and research priorities in the field of aller-
gic rhinitis and Chronic Respiratory Diseases were 
highlighted from the perspectives of the patients and 
clinicians. This meeting resulted in the definition of the 
research priorities in the field of CRD and the joint action 
plan to meet these priorities [20]. A follow-up meeting is 
planned in the Royal Academy of Medicine of Belgium 
in Brussels on November 9 and 10, 2017, involving basic 
researchers, clinicians, representatives of patient organi-
zations, and representatives of the industry and health 
authorities.
The role of scientific societies
European scientific societies are crucial in the manage-
ment of CRD. They provide evidence-based, state-of-the 
art guidance for health practitioners by means of publish-
ing research and knowledge including clinical practice 
guidelines, statements and technical standards as well 
as by providing continuing medical education (CME). In 
Fig. 5 EUFOREA online Patient Educational Platform
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addition, the large-scale annual or bi-annual congresses 
aim at transferring the latest scientific data to the clini-
cians. They bridge the gap between science and policy 
and advocate for policies committed to protecting pub-
lic health. Scientific societies need to provide evidence-
based input to ensure that airway diseases and their 
management is at the centre of policy decisions including 
air quality, European medical research, tobacco control 
and other preventative approaches such as occupational 
health issues. In conjunction with EFA, EAACI is cur-
rently launching a political Call to Action on Allergy and 
Asthma, with the support of the Interest Group on 
Allergy and Asthma of the European Parliament, led by 
the Finnish MEP Sirpa Pietikainen.
Prevention of allergy and asthma in Finland
In the early 1990s, the new paradigm of asthma as an 
inflammatory disease was implemented into practice 
by the Finnish Asthma Programme 1994–2004. This 
improved care and cut costs both for individual patients 
and society [21]. New information of immune devel-
opment in modern, urban societies has challenged the 
conventional thinking of allergy prevention. The Finn-
ish Allergy Programme 2008–2018 was initiated to turn 
avoidance strategy into tolerance strategy, and to take a 
step from treatment to prevention [22, 23]. Focusing on 
severe allergies and emphasizing allergy health rather 
than mild problems also targeted the use of health-care 
resources more efficiently. Revisiting of the asthma and 
allergy paradigms has led to actions relevant to society 
and health-care as a whole. In the Finnish society, burden 
of these conditions has started to decline [24]. The expe-
rience encourages medical communities and societies to 
lessen disability and costs caused by allergy and asthma 
and to improve public health.
Therapeutic strategies to prevent asthma
Asthma often starts early in life and tends to persist 
across the life cycle [2, 25]. Thus, asthma prevention is a 
continuum from conception (or even before) to old age, 
integrating the complex network of risk factors (genome, 
exposome and disease endotypes and phenotypes) into 
a detailed roadmap for action [26]. Today the projection 
of children’s diseases in adulthood is the key target for 
research and prerequisite of effective prevention as well 
as healthy ageing [27]. Wheezing is the major problem 
in both developed and developing countries affecting up 
to 50% of children under the age of 6  years. Even tran-
sient early wheeze is not only characterized by lower lung 
function but is also associated with chronic obstructive 
pulmonary disease in late adulthood [28]. An important 
work point is to protect children from active and passive 
smoking. Speed networking and new technologies based 
e-research allow different projects to be integrated as well 
as the building of roads to modern paediatric respiratory 
medicine in EU countries [29].
A step-wise pathway is proposed: the tomorrow action 
plan relies on the multi-strategy approach focused on 
primary prevention and including the targeted hygiene 
concept. The 5-year programme relies on the wide use of 
health information technology translating vast amounts 
of “real-world” data unbiased by any pre-selection crite-
ria into real-time clinical decision support at the point 
of care and harmonised disease management based on 
quality criteria [30]. The 10-year strategy integrates the 
multi-strategy approach with big data into personalised 
prevention plans [31]. Global, multi-discipline partner-
ships, rethinking healthcare, agreeing and implementing 
a fair balance between research and political priorities 
are all key points for an efficient asthma prevention strat-
egy [32].
Immunologic rationale for prevention of CRD
Dysregulated immune system, exposure to pollutants, 
irritants and allergens at home or to professional irri-
tants in the work environment [33, 34], schools and 
workplace, genetic factors, and respiratory infections 
all play a role in the increased prevalence of CRD [35, 
36]. Tobacco smoke is a key factor in the development 
and progression of CRD. Activation of the immune sys-
tem cells and their interaction with tissue cells followed 
by chronic inflammation is a key mechanism in their 
pathogenesis. A defect in allergen tolerance is the cause 
of allergic diseases and is based on immunologic mecha-
nisms. Recently, leakiness in the epithelial barrier is a 
major finding in all Chronic Respiratory Diseases such 
as asthma, AR and CRS [37, 38]. Several strategies are 
being developed to prevent respiratory diseases, includ-
ing the restoration of barrier deficiency. Identification of 
risk groups and early intervention to restore the barrier 
function are essential for successful prevention strategies 
[39–41].
A specific novel promising asthma prevention strategy 
resulted from the national survey in the United Kingdom
A prospective audit including more than 3 000 UK CRS 
surgical patients and assessing outcomes over a 5  year 
period showed significant improvement in the vast 
majority of patients [42]. Patients were then stratified by 
onset of symptoms to surgery into early (< 1 years), mid 
(1–5 years) and late (> 5 years) cohorts. This showed that 
the percentage change from baseline of CRS outcomes 
(SNOT22 scores) was greater in the early than in the late 
cohort at all time points (p < 0.005 at 1 years) when other 
demographic factors and extent of surgery were con-
trolled [43]. Asthma prevalence was significantly higher 
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in the late group, suggesting that earlier sinus surgery is 
associated with better outcomes in both the upper and 
lower respiratory tract, altering natural history and pre-
venting co-morbidities.
Strategies for broad implementation of effective self‑care
PROSTEP (Promotion of self-care in chronic diseases in 
the EU) is a tender designed to explore the added value of 
self-management in chronic diseases. It benefits from a 
thorough analysis of patient empowerment, including the 
relationship between self-management, joint decision-
making and health literacy. PROSTEP stemmed from the 
EMPATHiE project (Empowering patients in the man-
agement of chronic diseases http://www.eu-patient.eu/
whatwedo/Projects/EMPATHiE/), the first of two pre-
vious tenders, and from the experience of a platform of 
experts addressing the issues around the promotion of 
self-care in minor and self-limiting conditions (the PiSCE 
project). The overall requirements of this tender were 
(1) to conduct a study (consisting of a literature review 
and cost–benefit analysis) and (2) to set up a platform 
of experts in self-care in the field of chronic diseases to 
explore and propose possible methods of promotion of 
self-care for chronic diseases, taking into account pre-
vious and on-going policy work in this field such as the 
work of the CHRODIS JA. The 2-year project kicked off 
in January 2016.
Patient’s empowerment
The European Federation for Allergy and Airways Dis-
eases Patients’ Associations (EFA) has launched differ-
ent projects at EU level to empower patients. They are 
built on three pillars: education, self-management and 
advocacy. One of the projects, Hey Ya, aims at improv-
ing health literacy in adolescent patients via raising self-
awareness, confidence and attitude. This is particularly 
important in teenagers in whom poor adherence due 
to reduced health literacy is one of the major contribu-
tors to uncontrolled allergic airway disease. Secondly, 
the My Air Coach project was launched by the help of 
the Horizon 2020 Research and Innovation framework 
programme with the aim to develop a patient-friendly, 
sensor-based tool to collect clinical, environmental and 
behavioural data relating to the patient. Via self-manage-
ment, it is a powerful tool for the prevention of complica-
tions. mHealth technology, jointly with patients’ personal 
experience, are important for raising self-efficiency. 
Both Hey Ya and My Air Coach are important tools for 
improving teenagers’ approach toward the diseases. 
Lastly, EFA supports and actively participates in advo-
cacy campaigns at EU level. Recently, the Written Dec-
laration on Chronic Respiratory Diseases was closed and 
signed by 115 MEPs. A new ‘United Action for Allergy 
and Asthma’ was launched in the EU parliament in April 
2017 to improve public policies. It addresses allergy and 
asthma and supports patients’ rights.
Technology transfer in rhinitis and asthma
The European Innovation Partnership on Active and 
Healthy Ageing (EIP on AHA) includes 74 Reference 
Sites. Scaling up is an essential component of the Action 
Plan B3 of the EIP on AHA (chronic diseases and remote 
monitoring) [27, 44]. A transfer innovation from an App 
developed by the MACVIA-France EIP on AHA refer-
ence site (Allergy Diary) to other reference sites will 
compare the phenotypic characteristics of rhinitis and 
asthma in adults and old age people using validated ICT 
tools (Allergy Diary [19] and CARAT: Control of Allergic 
Rhinitis and Asthma Test [45]) in 25 Reference Sites or 
regions across Europe. The aim is to better understand, 
assess the burden, diagnose and manage rhinitis and 
asthma in old age people.
Conclusions
The high prevalence and major socio-economic impact 
of CRD require an inter-academic and multi-stakeholder 
approach for the successful implementation of preven-
tion strategies leading to cost savings and reduction of 
burden. EUFOREA will continue its’ mission to call for 
action by all stakeholders to implement Precision Medi-
cine as the tool to arrest the epidemic of CRD. In Europe, 
there is an urgent need to join forces in the education of 
patients and medical care providers on prevention strate-
gies, and to call for political action supported by all Euro-
pean academic stakeholders involved in the care of CRD.
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